New Blood Test for Cervical Cancer May Offer Fresh Approach to Screening
A groundbreaking study published in the medical journal BMJ has found that taking a sample from menstrual blood on a sanitary pad could be a more convenient and non-invasive way to screen for cervical cancer. The test, which detects human papillomavirus (HPV), is currently used under the care of a clinician who collects a sample via a brush inserted into the vagina, but many women fail to attend screenings.
Researchers in China compared the diagnostic accuracy of menstrual blood samples with those collected by clinicians for detecting cervical cell abnormalities, finding that the test was highly sensitive and comparable in performance to traditional methods. The study involved 3,068 women aged between 20 and 54 who provided three samples each: one taken from their sanitary pad, another via a clinician's brush, and a third processed in a lab.
The findings suggest that this new blood test could provide an alternative or replacement for cervical cancer screening, offering a more accessible option for millions of women worldwide. However, experts caution that further trials are needed to confirm its effectiveness and explore its potential use in existing screening pathways.
While the study's results are promising, there are also limitations to consider. For instance, not all women can participate due to menopausal status or other factors, highlighting the need for personalized approaches to screening.
As one expert noted, "people have different barriers and concerns about screening," and offering a range of options could be beneficial for those who currently avoid screenings but may be more willing to participate with a fresh approach like this new blood test.
A groundbreaking study published in the medical journal BMJ has found that taking a sample from menstrual blood on a sanitary pad could be a more convenient and non-invasive way to screen for cervical cancer. The test, which detects human papillomavirus (HPV), is currently used under the care of a clinician who collects a sample via a brush inserted into the vagina, but many women fail to attend screenings.
Researchers in China compared the diagnostic accuracy of menstrual blood samples with those collected by clinicians for detecting cervical cell abnormalities, finding that the test was highly sensitive and comparable in performance to traditional methods. The study involved 3,068 women aged between 20 and 54 who provided three samples each: one taken from their sanitary pad, another via a clinician's brush, and a third processed in a lab.
The findings suggest that this new blood test could provide an alternative or replacement for cervical cancer screening, offering a more accessible option for millions of women worldwide. However, experts caution that further trials are needed to confirm its effectiveness and explore its potential use in existing screening pathways.
While the study's results are promising, there are also limitations to consider. For instance, not all women can participate due to menopausal status or other factors, highlighting the need for personalized approaches to screening.
As one expert noted, "people have different barriers and concerns about screening," and offering a range of options could be beneficial for those who currently avoid screenings but may be more willing to participate with a fresh approach like this new blood test.